Because the use of dabigatran (Pradax™) as an anticoagulant for the treatment of atrial fibrillation (AF) presents significant therapeutic, economic, organizational and ethical challenges, INESSS has created a guide to promote its optimal use.

The optimal usage guide developed by INESSS is intended to put practical information close at hand in order to facilitate decision-making. It goes without saying that this guide should not replace the judgement of a professional. INESSS has also published a report to accompany this guide. In it, Québec-based practitioners can find data supporting the choices made by the committee of experts who assisted INESSS with this process. The guide and the report are available on the Web.

Note that the guide will be distributed by mail to all clinicians (physicians, residents, pharmacists and nurses, as well as 3rd- and 4th-year pharmacy and medicine students) in the coming weeks. Watch your mailbox!